Generon announces the initiation of a Phase 1 Clinical Trial for A-337
Generon Corporation announced the initiation of a clinical trial for A-337, a CD3-activating bi-specific antibody targeting EpCAM, in Australia. This is a “Phase I, Open-label,…
Read More...
Read More...